Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% – Still a Buy?
by Tristan Rich · The Markets DailyStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) shares rose 10.8% on Thursday . The stock traded as high as $54.48 and last traded at $55.6050. Approximately 279,959 shares traded hands during trading, a decline of 73% from the average daily volume of 1,043,011 shares. The stock had previously closed at $50.17.
Analyst Ratings Changes
A number of research firms have issued reports on GPCR. JPMorgan Chase & Co. boosted their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.00.
Check Out Our Latest Stock Report on Structure Therapeutics
Structure Therapeutics Price Performance
The stock’s 50 day moving average is $64.67 and its 200-day moving average is $52.40. The company has a market capitalization of $3.79 billion, a P/E ratio of -67.70 and a beta of -1.17.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). On average, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.
Institutional Investors Weigh In On Structure Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PEAK6 LLC purchased a new position in Structure Therapeutics during the fourth quarter valued at $553,000. Flax Pond Capital LLC purchased a new stake in shares of Structure Therapeutics in the 4th quarter worth about $3,389,000. XTX Topco Ltd bought a new position in shares of Structure Therapeutics in the 4th quarter worth about $1,335,000. Voloridge Investment Management LLC bought a new position in shares of Structure Therapeutics in the 4th quarter worth about $17,388,000. Finally, Vestal Point Capital LP purchased a new position in Structure Therapeutics during the 4th quarter valued at about $2,434,000. 91.78% of the stock is owned by hedge funds and other institutional investors.
Structure Therapeutics Company Profile
Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.